Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today.
Glaukos Corp (GKOS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 4,828 | $393,723 | +57% | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.84 | 2,100 | $50,064.00 | 102,100 | 2017-11-22 | Filing | |
| $16.03 | 2,500 | $40,075.00 | 5,000 | 2016-03-04 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 1,388 | 2015-12-31 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 4,656 | 2015-12-31 | Filing | |
| $21.83 | 2,500 | $54,575.00 | 2,500 | 2015-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $84.70 | 276 | $23,377.20 | 76,390 | 2025-09-22 | Filing | |
| $83.76 | 218 | $18,259.68 | 76,666 | 2025-09-22 | Filing | |
| $82.79 | 23 | $1,904.17 | 76,884 | 2025-09-22 | Filing | |
| $88.61 | 1,948 | $172,612.28 | 75,469 | 2025-09-11 | Filing | |
| $87.98 | 3,194 | $281,008.12 | 77,417 | 2025-09-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 569,644 | $46,454,445 | 0.78% | |
| 2. | 267,498 | $22,253,158 | 0.04% | |
| 3. | 157,545 | $12,847,795 | 0.02% | |
| 4. | 128,210 | $10,455,526 | 0.01% | |
| 5. | 31,175 | $2,542,321 | 0% |
News See All
Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel
Glaukos Corporation (NYSE:GKOS) ranks among the best medical device stocks to invest in.
12 Best Medical Device Stocks to Invest In Now
As chronic diseases like diabetes and cancer become more common, medical device technology is becoming increasingly innovative.
Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa
Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapies, continues to expand its presence in glaucoma, corneal disorders, and retinal diseases through innovative “...
13 Most Oversold Healthcare Stocks So Far in 2025
The healthcare innovation landscape in 2025 is navigating a complex mix of challenges and opportunities, marked by contrasting trends in fundraising, investment, and technology adoption.
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation's Second Quarter 2025 Financial Results Conference Call.
Here’s Why Glaukos (GKOS) Shares Traded Lower in Q1
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter.
Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation First Quarter 2025 Financial Results Conference Call.
What Makes Glaukos Corporation (GKOS) a Compelling Stock?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center Billionaire Hedge Funds
